Courtney Morris feat WebbMan Breedzy CanCan Kushic Just a track we put together of a subliminal concept when people will think we talking about drugs but really were talking about music is our only high.its a real good song and amazing concept so show love.i appreciate the time of listening and supporting. Recorded by Courtney Morris (Lil89Flex) Engineered by Courtney Morris Written by Courtney Morris, Marcus Webb, and Candace Breedlove By: MorrisCourtney … Continue reading →

Heart Attack Harry Styles Love Story Chapter 2 Autumn's POV **End of Autumn's Flashback** All f the thought's ran back through my mind as i sobbed even louder,someone even shouted from across the street "keep it down,crybaby".Life was always a struggle for me,but never this hard.Logan,Nicole,and Jennifer seemed happy Nicole was actually nice and was done with Chelsea's clique,but was also done with school,as well as Logan.i couldn't cope as well with all the events in the first few months,but it got better along the way.my dad did go on drugs,and eventually,i was hated by Chelsea,for some what no apparent reason,and Logan was gone forever and seemed happy about it,but i managed to be fine just by myself.I knew that i had to drop the nice girl act and man up if i wanted people to take me seriously.I knew i couldn't be just a soft girl with a broken life,i had to live if i wanted to survive.I wiped away my tears and went back into the cafeteria,and pounced on Chelsea.Before i ran out of the school,Chelsea was talking to her crew,about how my mom was a whore,and was selling sex,and got HIV … Continue reading →

Sleazy Happy New Year!!!!!!!! I just found out how to use the auto tune feature!!!!!!!!!! (Not that Im into it but, its cool to know how to use it.) Anywho, since "ratchet", being on drugs and treating women like shit is in, I thought I'd play around with the subject matter. (or lack thereof) Enjoy! Produced By: DJ Blaze Wave (DJBlazeWave) -2013 CityRandom-RandomCity- By: Rivers1129 … Continue reading →

Greystone Research Associates Finds High-Growth Markets Hinge on the Ability of Users to Safely and Reliably Reconsitute Solid Injectable Formulations (Amherst, NH) The ability of a growing number of New Chemical Entities (NCEs) to have commercial value as therapeutic drugs rests in the capability of developers to create formulations that render them stable at ambient temperatures. Once created, end users caregivers and patients must have a way to reconstitute them prior to administration. These requirements have fostered two industry segments designed to address the growing need for creating powder forms of injectables, and for developing devices that allow them to be reconstituted simply and without introducing medication errors. Growth in the number of injectable drugs supplied in solid form for reconstitution prior to administration is being driven by the increase in drugs based on biologicals. These drugs are typically unstable at ambient temperatures and to preserve their shelf life must be either stored at low temperature (the so-call 'cold chain') or processed into a form that will preserve their pharmacological efficacy until they are ready for use. Because the cost of transporting and storing drugs using refrigeration is expensive and requires constant temperature monitoring to insure that the drug has … Continue reading →

SAN FRANCISCO, CA--(Marketwire - Jan 2, 2013) - The U.S. Food and Drug Administration approved eight new drugs in December pushing the year's total to 39, its highest level since 1996 when the agency cleared a backlog of applications. Though December's newly approved drugs cover a broad range of conditions, the agency had granted orphan drug status to six of the eight medicines. Orphan drug status confers financial and other benefits to a drug's sponsor to encourage the development of drugs to treat patient populations of 200,000 or less in the United States. In fact, nearly half of the 39 drugs approved in 2012 had orphan drug designations. "We've seen drugmakers embrace orphan drugs for a variety of reasons including the opportunity to win faster approvals and run smaller, less costly clinical trials, and better chances of success," says G. Steven Burrill, CEO of Burrill & Company, a global financial services firm focused on the life sciences. "The passage in 2012 of new incentives for developing rare disease drugs will only further fuel this trend, particularly as more precision therapies are developed to target subpopulations of patients with a given disease." Trading activity of biotech stocks echoed the positive year … Continue reading →

ROCKVILLE, MD--(Marketwire - Jan 2, 2013) - MarketResearch.com has announced the addition of the market research report "Orphan Drugs: Market Environment Products and Companies" to their product offering. The combination of government incentives to develop drugs for rare diseases and the promise of commercial opportunity will continue to fuel the industry's interest in orphan drugs; and provide hope to patients with debilitating conditions and high unmet medical needs. In addition, the fast track approval system allows companies to enter the market faster and more cost-effectively with the potential to extend indications. While orphan diseases are rare, patients with rare diseases are numerous. There are up to 7,000 identifiable rare diseases, affecting an estimated 622 million people around the world. There is a clear need to provide rare disease patients with the same quality of care as other patients, and governments have provided incentives to companies developing orphan drugs to address a significant public health need. As effective diagnostics play a greater role in accurately diagnosing orphan diseases, the addressable patient population will expand. One of the biggest challenges for rare disease patients is obtaining the correct diagnosis, which can be extremely difficult and can take years, or even decades. An … Continue reading →